Literature DB >> 20851799

Genetic alterations in children and adolescents with acute myeloid leukaemia.

Amparo Verdeguer1.   

Abstract

Acute Myeloid Leukemia is a clinically and genetically heterogeneous disease, in which cytogenetic aberrations are the most important factors to determine biological behavior and prognosis. More than 20 different chromosomal abnormalities have been identified in a high percentage of children (70-85%) with the novo AML. We reviewed the most frequently found and the impact of these aberrations on prognosis. Differences according to the age of patients and mainly in relation to adult population have been enhanced, although the low incidence of AML in children and the high number of abnormalities make difficult to accurately define the prognosis significance of these aberrations.

Entities:  

Mesh:

Year:  2010        PMID: 20851799     DOI: 10.1007/s12094-010-0563-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  66 in total

1.  Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption.

Authors:  Stefan Meyer; William D Fergusson; Anthony D Whetton; Flavia Moreira-Leite; Stuart D Pepper; Crispin Miller; Emma K Saunders; Daniel J White; Andrew M Will; Tim Eden; Hideyuki Ikeda; Reinhard Ullmann; Seval Tuerkmen; Antje Gerlach; Eva Klopocki; Holger Tönnies
Journal:  Genes Chromosomes Cancer       Date:  2007-04       Impact factor: 5.006

2.  Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.

Authors:  Y Ravindranath; M Chang; C P Steuber; D Becton; G Dahl; C Civin; B Camitta; A Carroll; S C Raimondi; H J Weinstein
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

Review 3.  Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era.

Authors:  T A Alonzo; R J Wells; W G Woods; B Lange; R B Gerbing; A B Buxton; S Neudorf; J Sanders; F O Smith; S A Feig
Journal:  Leukemia       Date:  2005-06       Impact factor: 11.528

4.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Authors:  Christian Thiede; Sina Koch; Eva Creutzig; Christine Steudel; Thomas Illmer; Markus Schaich; Gerhard Ehninger
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

Review 5.  t(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia.

Authors:  S Tosi; J Harbott; A Teigler-Schlegel; O A Haas; H Pirc-Danoewinata; C J Harrison; A Biondi; G Cazzaniga; H Kempski; S W Scherer; L Kearney
Journal:  Genes Chromosomes Cancer       Date:  2000-12       Impact factor: 5.006

6.  Multipoint interphase FISH analysis of chromosome 3 abnormalities in 28 childhood AML patients.

Authors:  Irén Haltrich; Maria Kost-Alimova; Gábor Kovács; George Klein; György Fekete; Stefan Imreh
Journal:  Eur J Haematol       Date:  2006-02       Impact factor: 2.997

7.  High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

Authors:  Sanne Lugthart; Ellen van Drunen; Yvette van Norden; Antoinette van Hoven; Claudia A J Erpelinck; Peter J M Valk; H Berna Beverloo; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

8.  Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

Authors:  Verena Ingeborg Gaidzik; Richard Friedrich Schlenk; Simone Moschny; Annegret Becker; Lars Bullinger; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

9.  The incidence and clinical significance of nucleophosmin mutations in childhood AML.

Authors:  Patrick Brown; Emily McIntyre; Rachel Rau; Soheil Meshinchi; Norman Lacayo; Gary Dahl; Todd A Alonzo; Myron Chang; Robert J Arceci; Donald Small
Journal:  Blood       Date:  2007-04-17       Impact factor: 22.113

10.  Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

Authors:  Susan P Whitman; Amy S Ruppert; Guido Marcucci; Krzysztof Mrózek; Peter Paschka; Christian Langer; Claudia D Baldus; Jing Wen; Tamara Vukosavljevic; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Michael A Caligiuri; Clara D Bloomfield
Journal:  Blood       Date:  2007-03-06       Impact factor: 22.113

View more
  1 in total

1.  A Multicenter Experience from Lebanon in Childhood and Adolescent Acute Myeloid Leukemia: High rate of Early Death in Childhood Acute Promyelocytic Leukemia.

Authors:  Roula A Farah; Jessy G Horkos; Youssef D Bustros; Hussein Z Farhat; Oussama Abla
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-01-01       Impact factor: 2.576

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.